Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ibrutinib (Imbruvica®) cannot be endorsed for use within NHS Wales as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). |
||
|
||
Medicine details |
||
| Medicine name | ibrutinib (Imbruvica®) | |
| Formulation | Capsule | |
| Reference number | 3279 | |
| Indication | Single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/09/2016 | |